Mizuho Has Lowered Expectations for Inspire Medical Systems (NYSE:INSP) Stock Price

Inspire Medical Systems (NYSE:INSP) had its price objective reduced by research analysts at Mizuho from $70.00 to $55.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Mizuho’s price objective would suggest a potential upside of 19.94% from the company’s current price.

A number of other analysts have also recently commented on the company. Evercore reiterated an “outperform” rating on shares of Inspire Medical Systems in a research report on Friday, February 27th. Wells Fargo & Company set a $70.00 price objective on Inspire Medical Systems and gave the company an “equal weight” rating in a research report on Thursday, February 12th. Zacks Research cut Inspire Medical Systems from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 14th. UBS Group set a $67.00 price objective on Inspire Medical Systems in a research report on Friday, February 13th. Finally, Jefferies Financial Group reduced their price objective on Inspire Medical Systems from $81.00 to $66.00 and set a “hold” rating for the company in a research report on Thursday, February 12th. Four equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Inspire Medical Systems presently has a consensus rating of “Hold” and a consensus target price of $85.00.

Inspire Medical Systems Price Performance

INSP stock opened at $45.86 on Tuesday. Inspire Medical Systems has a 1-year low of $44.41 and a 1-year high of $163.35. The business has a fifty day moving average price of $56.26 and a 200-day moving average price of $79.20. The stock has a market capitalization of $1.32 billion, a P/E ratio of 10.21, a P/E/G ratio of 5.40 and a beta of 0.83.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings data on Monday, May 4th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.38. The company had revenue of $204.58 million during the quarter, compared to analysts’ expectations of $200.04 million. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.Inspire Medical Systems’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.10 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, analysts anticipate that Inspire Medical Systems will post 0.84 earnings per share for the current year.

Institutional Trading of Inspire Medical Systems

Hedge funds have recently bought and sold shares of the stock. Y Intercept Hong Kong Ltd grew its holdings in Inspire Medical Systems by 553.1% during the third quarter. Y Intercept Hong Kong Ltd now owns 99,049 shares of the company’s stock valued at $7,349,000 after purchasing an additional 83,883 shares during the period. Illinois Municipal Retirement Fund grew its holdings in Inspire Medical Systems by 262.0% during the third quarter. Illinois Municipal Retirement Fund now owns 25,424 shares of the company’s stock valued at $1,886,000 after purchasing an additional 18,400 shares during the period. Regal Partners Ltd bought a new stake in Inspire Medical Systems during the third quarter valued at about $7,547,000. Aberdeen Group plc grew its holdings in Inspire Medical Systems by 16.3% during the fourth quarter. Aberdeen Group plc now owns 460,901 shares of the company’s stock valued at $42,509,000 after purchasing an additional 64,561 shares during the period. Finally, State of New Jersey Common Pension Fund D grew its holdings in Inspire Medical Systems by 79.9% during the third quarter. State of New Jersey Common Pension Fund D now owns 23,216 shares of the company’s stock valued at $1,723,000 after purchasing an additional 10,311 shares during the period. Institutional investors own 94.91% of the company’s stock.

Key Inspire Medical Systems News

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q1 beat consensus on both EPS and revenue, demonstrating underlying demand despite near-term headwinds. This supports the company’s fundamentals even as guidance was trimmed. Zacks: Q1 Beat
• Positive Sentiment: Stifel maintained a “buy” rating despite lowering its price target (from $70 to $65), signaling some analyst conviction in longer?term upside. Benzinga: Stifel
• Neutral Sentiment: Bank of America reaffirmed its “neutral” rating with a $53 target, reflecting a balanced view between recovery potential and short?term execution risk. Finviz: BofA
• Negative Sentiment: Management cut FY?2026 guidance (revenue range reported ~ $825M–$875M) and cited coding/reimbursement disruptions and WISeR-program impacts on procedure volume — the primary reason investors are concerned about near?term growth. Seeking Alpha: Guidance Cut
• Negative Sentiment: Multiple brokerages lowered price targets and/or ratings following the print — notable moves include Robert W. Baird to $50 (neutral), Mizuho to $55 (outperform), JPMorgan to $54 (neutral), Truist to $50 (hold), and Wells Fargo to $56 (equal weight). The breadth of cuts is amplifying selling pressure. Baird article Mizuho article
• Negative Sentiment: Analyst commentary remains mixed-to-bearish: a recent write-up keeps a “sell” stance post?earnings, highlighting execution and reimbursement risks that could weigh on the stock for weeks. Seeking Alpha: Sell Rating

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.